Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

Welcoming the latest member of the Porterhouse Medical Advisory Group

Porterhouse is proud to announce that our Medical Advisory Group (MAG) has grown once again, adding further clinical experience to our existing pool of knowledge and real-world insights.We are delighted...

Porterhouse Medical Group

- PMLiVE

Is creativity in quarantine?

Chris Ross explores the value of creativity – and how to realise it

- PMLiVE

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Combination treatment topped Pfizer's Sutent in phase 3

- PMLiVE

AZ’s BTK inhibitor Calquence fails in COVID-19 study

Therapy is already approved to treat a number of blood cancers

Oxford University Press advertising and custom content team hosts their first ever virtual drop-in sessions

This is your chance to ask Oxford University Press anything: a quick question about advertising deadline dates for the European Heart Journal or a full presentation on the benefits of...

Oxford University Press

An update from Oxford University Press Advertising and Corporate Services

Angela Joines, our advertising and reprints manager in Cary, North Carolina, has recorded a quick message to give you a glimpse of how we’re getting on working remotely in these...

Oxford University Press

- PMLiVE

Moderna posts encouraging early data for personalised cancer vaccine

Vaccine tested alongside Merck's Keytruda

- PMLiVE

Shaping the organisation to enable intelligent, precision engagement

By Simon Grime

- PMLiVE

Pfizer, BioNTech set to price COVID-19 vaccine ‘well below typical market rates’

Chief strategy officer revealed plans at FT virtual event

- PMLiVE

AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients

- PMLiVE

Russia claims its COVID-19 vaccine is over 90% effective

Interim results come from first 16,000 participants to receive two doses of the vaccine

- PMLiVE

Sinovac’s late-stage COVID-19 vaccine trial paused in Brazil

Health regulator Anvisa reports that pause is due to severe adverse event

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links